Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets - PubMed (original) (raw)
Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets
S Costa et al. Eur J Pharmacol. 2001.
Abstract
Glial cell line-derived neurotrophic factor (GDNF) has previously reduced motor deficits and preserved nigral dopamine neurones in rhesus monkeys with a unilateral MPTP-induced lesion of substantia nigra. We now report on the ability of GDNF to reverse motor deficits induced by parenteral administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets resulting in bilateral degeneration of the nigrostriatal pathway. Prior to GDNF administration, all MPTP-treated animals showed akinesia or bradykinesia, rigidity, postural instability and tremor. Intraventricular injection of GDNF (10, 100 or 500 microg) at 9 and 13 weeks post MPTP treatment resulted in a concentration dependent improvement in locomotor activity and motor disability which became significant after administration of 100 and 500 microg of GDNF. The most prominent improvements were in alertness, checking movements, and posture. It is concluded that intraventricular GDNF administration improves bilateral Parkinsonian motor disability following MPTP treatment and this may reflect an action of GDNF on remaining nigral dopaminergic neurones.
Similar articles
- GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Iravani MM, Costa S, Jackson MJ, Tel BC, Cannizzaro C, Pearce RK, Jenner P. Iravani MM, et al. Eur J Neurosci. 2001 Feb;13(3):597-608. doi: 10.1046/j.1460-9568.2001.01408.x. Eur J Neurosci. 2001. PMID: 11168568 - GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.
Gerhardt GA, Cass WA, Huettl P, Brock S, Zhang Z, Gash DM. Gerhardt GA, et al. Brain Res. 1999 Jan 30;817(1-2):163-71. doi: 10.1016/s0006-8993(98)01244-x. Brain Res. 1999. PMID: 9889359 - Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.
Grondin R, Gash DM. Grondin R, et al. J Neurol. 1998 Nov;245(11 Suppl 3):P35-42. doi: 10.1007/pl00007744. J Neurol. 1998. PMID: 9808338 Review. - Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Xu G, Xiong Z, Yong Y, Wang Z, Ke Z, Xia Z, Hu Y. Xu G, et al. Neuroscience. 2010 Apr 28;167(1):174-84. doi: 10.1016/j.neuroscience.2010.01.048. Epub 2010 Feb 1. Neuroscience. 2010. PMID: 20123001 - Neuroprotective and neurorestorative properties of GDNF.
Gash DM, Zhang Z, Gerhardt G. Gash DM, et al. Ann Neurol. 1998 Sep;44(3 Suppl 1):S121-5. doi: 10.1002/ana.410440718. Ann Neurol. 1998. PMID: 9749583 Review.
Cited by
- Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.
Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q, Guo Y, Brown RH Jr, Gao G, Xu Z. Wang H, et al. Hum Mol Genet. 2014 Feb 1;23(3):668-81. doi: 10.1093/hmg/ddt454. Epub 2013 Sep 18. Hum Mol Genet. 2014. PMID: 24108104 Free PMC article. - Neurotrophic factors in neurodegenerative disorders : potential for therapy.
Fumagalli F, Molteni R, Calabrese F, Maj PF, Racagni G, Riva MA. Fumagalli F, et al. CNS Drugs. 2008;22(12):1005-19. doi: 10.2165/0023210-200822120-00004. CNS Drugs. 2008. PMID: 18998739 Review. - Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives.
El Ouaamari Y, Van den Bos J, Willekens B, Cools N, Wens I. El Ouaamari Y, et al. Int J Mol Sci. 2023 Feb 15;24(4):3866. doi: 10.3390/ijms24043866. Int J Mol Sci. 2023. PMID: 36835277 Free PMC article. Review. - Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review. - Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats.
Renko JM, Mahato AK, Visnapuu T, Valkonen K, Karelson M, Voutilainen MH, Saarma M, Tuominen RK, Sidorova YA. Renko JM, et al. J Parkinsons Dis. 2021;11(3):1023-1046. doi: 10.3233/JPD-202400. J Parkinsons Dis. 2021. PMID: 34024778 Free PMC article.